[1]
|
Sehn, L.H. and Salles, G. (2021) Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine, 384, 842-858. https://doi.org/10.1056/NEJMra2027612
|
[2]
|
Campo, E., Jaffe, E.S., Cook, J.R., et al. (2022) The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. Blood, 140, 1229-1253.
|
[3]
|
王艳君, 孟丹. 弥漫大B细胞淋巴瘤异质性研究进展[J]. 中国肿瘤临床与康复, 2009, 16(5): 455-457.
|
[4]
|
Pfreundschuh, M., Schubert, J., Ziepert, M., et al. (2008) Six versus Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab in Elderly Patients with Aggressive CD20 + B Cell Lymphomas: A Randomised Controlled Trial (RICOVER-60). The Lancet Oncology, 9, 105-116. https://doi.org/10.1016/S1470-2045(08)70002-0
|
[5]
|
Ennishi, D., His, E.D., Steidl, C., et al. (2020) Toward a New Molecular Taxonomy of Diffuse Large B-Cell Lymphoma. Cancer Discovery, 9, 1267-1281. https://doi.org/10.1158/2159-8290.CD-20-0174
|
[6]
|
Epperla, N., Vaughn, J.L., Othus, M., et al. (2020) Recent Survival Trends in Diffuse Large B-Cell Lymphoma—Have We Made Any Progress beyond Rituximab. Cancer Medi-cine, 9, 5519-5525. https://doi.org/10.1002/cam4.3237
|
[7]
|
杨漾, 张义成. 自体造血干细胞移植及CAR-T细胞疗法在复发/难治弥漫性大B细胞淋巴瘤中的应用进展[J]. 临床血液学杂志, 2023, 36(9): 622-626. https://doi.org/10.13201/j.issn.1004-2806.2023.09.003
|
[8]
|
Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gas-coyne, R.D., Delabie, J., Ott, G., et al. (2004) Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray. Blood, 103, 275-282. https://doi.org/10.1182/blood-2003-05-1545
|
[9]
|
Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Pat-more, R., Roman, E. and Jack, A. (2010) Rearrangement of MYC Is Associated with Poor Prognosis in Patients with Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab. Journal of Clinical Oncology, 28, 3360-3365. https://doi.org/10.1200/JCO.2009.26.3947
|
[10]
|
Rosenthal, A. and Younes, A. (2017) High Grade B-Cell Lym-phoma with Rearrangements of MYC and BCL2 and/or BCL6: Double Hit and Triple Hit Lymphomas and Double Ex-pressing Lymphoma. Blood Reviews, 31, 37-42.
https://doi.org/10.1016/j.blre.2016.09.004
|
[11]
|
Dent, A.L., Vasanwala, F.H. and Toney, L.M. (2002) Regulation of Gene Expression by the Proto-Oncogene BCL-6. Critical Reviews in Oncology/Hematology, 41, 1-9. https://doi.org/10.1016/S1040-8428(01)00164-0
|
[12]
|
Beaulieu, M.E., Castillo, F. and Soucek, L. (2020) Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein. Cells, 9, Article No. 1038. https://doi.org/10.3390/cells9041038
|
[13]
|
Wei, M.C. (2004) Bcl-2-Related Genes in Lymphoid Neoplasia. Interna-tional Journal of Hematology, 80, 205-209.
https://doi.org/10.1532/IJH97.04110
|
[14]
|
Leeman-Neill, R.J. and Bhagat, G. (2018) BCL6 as a Therapeutic Target for Lymphoma. Expert Opinion on Therapeutic Targets, 22, 143-152. https://doi.org/10.1080/14728222.2018.1420782
|
[15]
|
钟幸, 余娜莎, 刘志良, 等. “双表达”与“双打击”淋巴瘤临床特征、生存及预后因素分析[J]. 实用癌症杂志, 2022, 37(1): 150-153.
|
[16]
|
许彭鹏, 赵维莅. 中国临床肿瘤学会淋巴瘤诊疗指南解读之弥漫性大B细胞淋巴瘤的规范治疗[J]. 华西医学, 2019, 34(4): 351-354.
|
[17]
|
Duffy, M.J., O’Grady, S., Tang, M. and Crown, J. (2021) MYC as a Target for Cancer Treatment. Cancer Treatment Reviews, 94, Article ID: 102154. https://doi.org/10.1016/j.ctrv.2021.102154
|
[18]
|
张炜, 沈克锋, 张美兰, 等. 中国人群中弥漫性大B细胞淋巴瘤基于基因变异的分型及其预后意义[J]. 内科急危重症杂志, 2022, 28(3): 186-190.
|
[19]
|
Rosenwald, A., Wright, G., Chan, W.C., et al. (2002) The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. The New England Journal of Medicine, 346, 1937-1947.
https://doi.org/10.1056/NEJMoa012914
|
[20]
|
沈昊, 李超群, 郭玉娇, 等. 伊布替尼治疗B细胞恶性肿瘤的疗效和安全的单臂Meta分析[J]. 药学与临床研究, 2022, 30(5): 434-440. https://doi.org/10.13664/j.cnki.pcr.2022.05.005
|
[21]
|
王根, 李红红. 伊布替尼联合R-CHOP化疗方案在弥漫大B细胞淋巴瘤治疗中的临床效果分析[J]. 名医, 2022(13): 165-167.
|
[22]
|
Seshadri, M.R. and Melnick, A.M. (2022) Targeting MALT1 for the Treatment of Diffuse Large B-Cell Lymphoma. Leukemia & Lymphoma, 63, 789-798. https://doi.org/10.1080/10428194.2021.1999444
|
[23]
|
Schmitz, R., Wright, G.W., Huang, D.W., Johnson, C.A., Phelan, J.D., Wang, J.Q., et al. (2018) Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine, 378, 1396-1407.
https://doi.org/10.1056/NEJMoa1801445
|
[24]
|
徐卫, 梁金花. 弥漫大B细胞淋巴瘤新基因分型及分子靶向的治疗进展[J]. 临床血液学杂志, 2020, 33(9): 594-598. https://doi.org/10.13201/j.issn.1004-2806.2020.09.002
|
[25]
|
Chapuy, B., Stewart, C., Dunford, A.J., Kim, J., Kamburov, A., Redd, R.A., et al. (2018) Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct Pathogenic Mechanisms and Outcomes. Nature Medicine, 24, 679-690. https://doi.org/10.1038/s41591-018-0016-8
|
[26]
|
Wright, G.W., Huang, D.W., Phelan, J.D., Coulibaly, Z.A., Roulland, S., Young, R.M., et al. (2020) A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell, 37, 551-568.e14. https://doi.org/10.1016/j.ccell.2020.03.015
|
[27]
|
赵凯祺, 苏丽萍. MICM分型在弥漫大B细胞淋巴瘤中的作用研究进展[J]. 陕西医学杂志, 2023, 52(9): 1275-1278.
|
[28]
|
Lacy, S.E., Barrans, S.L., Beer, P.A., Painter, D., Smith, A.G., Roman, E., et al. (2020) Targeted Sequencing in DLBCL, Molecular Subtypes, and Outcomes: A Haematological Malignancy Research Network Report. Blood, 135, 1759-1771. https://doi.org/10.1182/blood.2019003535
|
[29]
|
Liang, X.J., Song, X.Y., Wu, J.L., Liu, D., Lin, B.Y., Zhou, H.S. and Wang, L. (2022) Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma. International Journal of Biological Sciences, 18, 1313-1327.
https://doi.org/10.7150/ijbs.67892
|
[30]
|
Grommes, C., Pastore, A., Palaskas, N., Tang, S.S., Campos, C., Schartz, D., et al. (2017) Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Dis-covery, 7, 1018-1029.
https://doi.org/10.1158/2159-8290.CD-17-0613
|
[31]
|
Ling, Y., Tao, M.X., De, Y.W., et al. (2023) Structural Clas-sification of EZH2 Inhibitors and Prospects for the Treatment of Tumor: A Review. Medicinal Chemistry Research, 32, 1589-1604.
https://doi.org/10.1007/s00044-023-03105-y
|
[32]
|
李佳苗, 曹小梅, 李冬菊, 等. 18F-FDG PET/CT扩散参数联合肿瘤代谢体积评估弥漫大B细胞淋巴瘤患者预后[J/OL]. 中国医学影像技术, 2023: 1-9. http://kns.cnki.net/kcms/detail/11.1881.R.20230926.1417.026.html
|